Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryushi Tazawa

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Respiratory Medicine|November 25, 2011
Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosisKazumasa Ohashi, Atsuyasu Sato, Toshinori Takada, et al.
Infectious Diseases (London, England)|September 20, 2023
Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trialShigeki Shimasaki, Tomohisa Baba, Takashi Ogura, et al.
Annals of the American Thoracic Society|May 11, 2017
A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar ProteinosisSayoko Tokura, Masanori Akira, Tomohisa Okuma, et al.
Annals of the American Thoracic Society|August 12, 2016
Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with LymphangioleiomyomatosisToshinori Takada, Ayako Mikami, Nobutaka Kitamura, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosisRyushi Tazawa, Bruce C Trapnell, Yoshikazu Inoue, et al.
American Journal of Respiratory and Critical Care Medicine|November 11, 2006
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasisHuqun, Shinyu Izumi, Hitoshi Miyazawa, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 16, 2018
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 14, 2018
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Respiration; International Review of Thoracic Diseases|December 12, 2022
Quantitative Evaluation of Changes in Three-Dimensional CT Density Distributions in Pulmonary Alveolar Proteinosis after GM-CSF InhalationMiku Oda, Kentaro Yamaura, Haruyuki Ishii, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 8, 2019
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Respiratory Medicine|November 25, 2011
Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosisKazumasa Ohashi, Atsuyasu Sato, Toshinori Takada, et al.
Infectious Diseases (London, England)|September 20, 2023
Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trialShigeki Shimasaki, Tomohisa Baba, Takashi Ogura, et al.
Annals of the American Thoracic Society|May 11, 2017
A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar ProteinosisSayoko Tokura, Masanori Akira, Tomohisa Okuma, et al.
Annals of the American Thoracic Society|August 12, 2016
Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with LymphangioleiomyomatosisToshinori Takada, Ayako Mikami, Nobutaka Kitamura, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosisRyushi Tazawa, Bruce C Trapnell, Yoshikazu Inoue, et al.
American Journal of Respiratory and Critical Care Medicine|November 11, 2006
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasisHuqun, Shinyu Izumi, Hitoshi Miyazawa, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 16, 2018
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 14, 2018
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Respiration; International Review of Thoracic Diseases|December 12, 2022
Quantitative Evaluation of Changes in Three-Dimensional CT Density Distributions in Pulmonary Alveolar Proteinosis after GM-CSF InhalationMiku Oda, Kentaro Yamaura, Haruyuki Ishii, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 8, 2019
Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysisHiroki Maruyama, Kaori Miyata, Mariko Mikame, et al.
Pageof 6